Westlake Village BioPartners
Venture capitalLos Angeles · Pre-Seed–Series A · 13 people tracked
Also known as WESTLAKE BIOPARTNERS, LLC
Investment thesis
The firm takes a people-first, company-creation approach to life science investing, crafting and incubating a concentrated portfolio of biotech companies around world-class entrepreneurs. Deeply embedded in the Los Angeles biotech ecosystem it helped catalyze, it is intentionally scaled to offer close, hands-on relationships with founders, guiding companies from ideation and preclinical research through clinical and commercial impact. The firm emphasizes empowering the right people, providing personal attention, capital, and access to a complementary network of innovation and community, with the goal of turning scientific breakthroughs into life-saving medicines that address the greatest unmet patient needs in California and beyond.
Source: firm website, verified Aug 25, 2026.
Team · 13 people
from the firm's website & public directories
What they invest in
from 19 of 28 portfolio companiesBiotech ×18Healthtech ×10AI & Machine Learning ×4Digital Health ×4Medical Devices ×4Deep Tech ×3Longevity ×1
HQs:United States×15
Investments · 28 tracked
founders shown can be your intro pathBy year:2025 · 42024 · 12021 · 49 dated
BiotechMenlo Park, US
Rekha Hemrajani(Executive Officer)Merdad Parsey(Executive Officer, Director)
BoardDavid Mott(Director)James Young(Director)Robert Garland(Director)
Board seatBeth Seidenberg· per SEC Form D · $80M raise · filed Jan 2021
Co-investorsKleiner Perkins
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)
Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio Partners+1 more
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.
BiotechDeep TechDigital HealthMedical Devices
Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)
Co-investorsVersant Ventures
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inJoseph G. Azofeifa(Executive Officer, Director)Laura Norris(Executive Officer, Director)Timothy Read(Executive Officer, Director)Eric Martin(Executive Officer)
BoardAmit Mehta(Director)
Board seatDavid AllisonMira Chaurushiya· per SEC Form D · $35.3M raise · filed Nov 2025
Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorBoxOne Ventures+1 more
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Kenneth Drazan(Executive Officer, Director)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)
BoardValentin Barsan(Director)
Board seatBeth Seidenberg· per SEC Form D
Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsOUP (Osage University Partners)SoftBank Vision Fund
HealthtechSeattle, US
John D. Hoekman(Executive Officer, Director)
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatDavid Allison· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio Global StrategicvenBio Partners
Latigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk.
BiotechHealthtechThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardJim Tananbaum(Director)Deborah Palestrant(Director)inKevin Raidy(Director)
Board seatBeth Seidenberg· per SEC Form D · $150M raise · filed Feb 2025
Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi Ventures5AM Ventures
Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)in
Board seatDavid Allison· per SEC Form D · filed Jul 2021
Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalvenBio Global Strategic
BiotechSan Francisco, US
Kristine M Ball(Executive Officer, Director)Zachary Hill(Executive Officer, Director)
BoardNisha Marathe(Director)Keno Gutierrez(Director)David Morris(Director)
Board seatDavid Allison· per SEC Form D · $42.2M raise · filed May 2021
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)Jason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)
Board seatBeth Seidenberg· per SEC Form D · $125M raise · filed Oct 2025
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more
3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
K. Christopher GarciaMarvin Gee(Founder)in
Co-investorsAsset Management CompanyCRV (Charles River Ventures)Menlo VenturesOS FundStarlight Ventures
Clinical stage company developing a small molecule pan-ROCK inhibitor targeting pulmonary and fibrotic indications.
AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.
BiotechNatick, US
Catherine Pearce(CEO & Founder)Catherine J. Pearce(Founder)DHSc(Founder)Justin R Thompson(Founder)
Co-investorsVersant VenturesWestlake BioPartners
A clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer.
Borealis develops RNA medicines to treat kidney diseases.
BiotechDigital Health
A clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)Matthew Fust(Director)Nancy Stagliano, Ph.D.(Director)
Co-investorsOrbiMedRA CapitalNVIDIA
A patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases.
BiotechSan Diego, US
Kevin Forrest, Ph.D.(Executive Officer, Director)
BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)
Co-investorsOsage University PartnersVersant Ventures
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
Biotech
Co-investorsVida Ventures
Clinical-stage biotech developing non-opioid pain medicines targeting pain transduction.
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsKleiner PerkinsSoftBank GroupSoftBank Vision Fund
Oorja Bio is a biotechnology company developing therapies focused on fibrotic disease, aiming to repair, reverse, and remodel fibrosis.
BiotechHealthtech
Sujay Kango(Chief Executive Officer & Founder)Janethe Pena(Chief Medical Officer & Founder)inConnie Coulomb(Chief Business Officer & Founder)
Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
Nancy Whiting(CEO)
Co-investorsAccess BiotechnologyNew Enterprise Associates (NEA)
Biotech developing therapies for rare diseases.
Cell therapy company now part of Kite, a Gilead Company, focused on treating cancer.
Preclinical stage company developing next-generation biologics for migraine prevention.
Clinical stage biotech developing first-in-class therapies for rare blood disorders, starting with von Willebrand disease.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolio3-V BiosciencesNASDAQ: SGMTAlumisNASDAQ: ALMS
Portfolio news
latest coverage across their companies
Latigo Bio · labusinessjournal.com · Aug 17, 2026
Alumis · stocktitan.net · Aug 13, 2026
Electra Therapeutics · geekwire.com · Jul 13, 2026
Star Therapeutics · pharmaceutical-technology.com · Oct 1, 2025
Arsenal Biosciences · fiercebiotech.com · Sep 17, 2025
Neuron23 · finsmes.com · Jun 25, 2025
Frequently asked questions
- How many investments has Westlake Village BioPartners made?
- Westlake Village BioPartners has 22 tracked investments, including 2 dated in the last 24 months.
- What stage does Westlake Village BioPartners invest at?
- Westlake Village BioPartners invests at the Pre-Seed, Seed, Series A stages.
- What is Westlake Village BioPartners's typical check size?
- Westlake Village BioPartners typically writes checks of $100K – $5M.
- What sectors does Westlake Village BioPartners focus on?
- Westlake Village BioPartners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Westlake Village BioPartners located?
- Westlake Village BioPartners is headquartered in Los Angeles, US.
- Does Westlake Village BioPartners lead rounds?
- Westlake Village BioPartners typically participates in rounds rather than leading them.
- Who does Westlake Village BioPartners co-invest with?
- Westlake Village BioPartners most often shares deals with Kleiner Perkins, OrbiMed, SoftBank Vision Fund, among 18 tracked co-investors.
Media · Podcasts & interviews
featuring the teamSean Harper -- Westlake Village BioPartners
LA Venture · Sean Harper
Images
Co-investors · 13
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Celesta Capital is a venture capital firm that invests in deep tech companies at the forefront of science and engineering.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
▶1 more co-investors
Firms observed investing alongside Westlake Village BioPartners, from public investor directories. Shared companies are the overlap with Westlake Village BioPartners's recorded portfolio.
Similar investors
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.